Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Atyr Pharma Inc. (ATYR:NASDAQ), powered by AI.
Atyr Pharma Inc. is currently trading at $0.53. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Atyr Pharma Inc. on Alpha Lenz.
View Atyr Pharma Inc.'s valuation metrics on Alpha Lenz.
“Atyr Pharma Inc.'s ROE is -107.8%. Explore profitability and growth together.”
Ask for details →Atyr Pharma Inc. is a biotechnology company dedicated to developing novel therapeutics based on innovative biological pathways. The company harnesses the unique therapeutic potential of extracellular proteins called tRNA synthetases, which play a critical role in cellular communication and regulation of immune responses. By leveraging these proteins, Atyr Pharma aims to create treatments for various diseases with unmet medical needs, most notably focusing on fibrotic lung diseases, cancer, and inflammation-related disorders. Its lead clinical program targets interstitial lung diseases, an area where significant therapeutic advancements are needed. Atyr Pharma Inc. operates within the competitive biotechnology sector, contributing to cutting-edge medical research and development. Headquartered in San Diego, California, the company collaborates with academic institutions and industry partners to advance its scientific discoveries from the laboratory to clinical testing stages, significantly impacting the scientific community and healthcare markets.
“Atyr Pharma Inc.'s ROE is -107.8%. Explore profitability and growth together.”
Ask for details →Atyr Pharma Inc. (ticker: ATYR) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 56 employees.
The current price is $0.53 with a P/E ratio of -x and P/B of -x.
ROE is -107.81% and operating margin is -40856.32%. Annual revenue is $190,000.